



Clinical trial results:

A double-blind, randomized, cross-over, multi-center efficacy and safety study of ibuprofen plus hyoscine butylbromide for pain management due to primary dysmenorrhea

Summary

EudraCT number	2022-000843-57
Trial protocol	BG
Global end of trial date	09 April 2024

Results information

Result version number	v1 (current)
This version publication date	19 February 2025
First version publication date	19 February 2025
Summary attachment (see zip file)	Synopsis (CRO22001_CSR_SYN_V1.0_09-Apr-2024_redacted.pdf)

Trial information

Trial identification

Sponsor protocol code	CRO22001
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	RONTIS HELLAS S.A.
Sponsor organisation address	38 Sorou St., Maroussi, Greece, GR15125
Public contact	Project Manager, RONTIS HELLAS S.A., +30 2106109090, agni.grypioti@rontis.com
Scientific contact	Project Manager, RONTIS HELLAS S.A., +30 2106109090, agni.grypioti@rontis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 April 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 April 2024
Global end of trial reached?	Yes
Global end of trial date	09 April 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of a combination of ibuprofen plus hyoscine butylbromide as compared to ibuprofen alone and hyoscine butylbromide alone for the management of pain due to primary dysmenorrhea.

Protection of trial subjects:

This trial was conducted in accordance with the ethical principles of Good Clinical Practice, according to the ICH Harmonized Tripartite Guideline and the local laws and regulations of the countries of clinical sites.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 January 2023
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 54
Worldwide total number of subjects	54
EEA total number of subjects	54

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	54
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study population consisted of female patients, 18 to 40 years old with a history of primary dysmenorrhoea and moderate to severe pain in at least 5 of the last 6 menstrual cycles.

Pre-assignment

Screening details:

The Screening Period lasted up to 30 days before start of treatment. A total of 57 subjects were screened. A total of 55 subjects were randomized and 54 of them were treated with study medication (full analysis set). 53 patients completed the trial.

Period 1

Period 1 title	Treatment (overall trial) (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	Test

Arm description: -

Arm type	Experimental
Investigational medicinal product name	ibuprofen plus hyoscine butylbromide
Investigational medicinal product code	Test IMP (T)
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

one hard capsule three times per day (=1200 mg ibuprofen and 60 mg hyoscine butylbromide)

Arm title	REFERENCE 1
------------------	-------------

Arm description:

Brufen 400 mg

Arm type	Active comparator
Investigational medicinal product name	Brufen 400 mg
Investigational medicinal product code	Reference 1 IMP (R1)
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

one hard capsule three times per day (=1200 mg ibuprofen)

Arm title	REFERENCE 2
------------------	-------------

Arm description:

Buscopan 10 mg

Arm type	Active comparator
Investigational medicinal product name	Buscopan 10 mg
Investigational medicinal product code	Reference 2 IMP (R2)
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

one hard capsule three times per day (= 60 mg hyoscine butylbromide)

Number of subjects in period 1	Test	REFERENCE 1	REFERENCE 2
Started	54	53	53
Completed	53	53	53
Not completed	1	0	0
randomized by mistake	1	-	-

Baseline characteristics

Reporting groups

Reporting group title	Treatment (overall trial)
-----------------------	---------------------------

Reporting group description: -

Reporting group values	Treatment (overall trial)	Total	
Number of subjects	54	54	
Age categorical			
Units: Subjects			
below 18 years	0	0	
18-30 years	29	29	
31-40 years	24	24	
over 40 years	1	1	
Age continuous			
Units: years			
arithmetic mean	29.1		
standard deviation	± 7.1	-	
Gender categorical			
Units: Subjects			
Female	54	54	
Male	0	0	
Race			
Units: Subjects			
White	54	54	
American Indian or Alaska Native	0	0	
Black or African American	0	0	
Asian	0	0	
Native Hawaiian or Other Pacific Islander	0	0	
Multiple	0	0	
Height			
Units: cm			
arithmetic mean	165.8		
standard deviation	± 4.88	-	
Weight			
Units: kg			
arithmetic mean	62.4		
standard deviation	± 15.5	-	
BMI			
Units: kg/m ²			
arithmetic mean	22.6		
standard deviation	± 5.06	-	

End points

End points reporting groups

Reporting group title	Test
Reporting group description: -	
Reporting group title	REFERENCE 1
Reporting group description: Brufen 400 mg	
Reporting group title	REFERENCE 2
Reporting group description: Buscopan 10 mg	
Subject analysis set title	per protocol
Subject analysis set type	Full analysis
Subject analysis set description: Treatment (overall period)	

Primary: AUC(0-4h)

End point title	AUC(0-4h) ^[1]
End point description:	
End point type	Primary
End point timeframe: Treatment (overall period)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The synopsis of the study report was attached.

End point values	per protocol			
Subject group type	Subject analysis set			
Number of subjects analysed	54			
Units: ng*h/ml				
geometric mean (standard deviation)				
T vs R1	0.28 (± 0.6354)			
T vs R2	0.47 (± 0.8025)			

Statistical analyses

No statistical analyses for this end point

Secondary: AUC(0-2h)

End point title	AUC(0-2h)
End point description:	
End point type	Secondary

End point timeframe:

Treatment (overall period)

End point values	per protocol			
Subject group type	Subject analysis set			
Number of subjects analysed	54			
Units: ng*h/ml				
geometric mean (standard deviation)				
T vs R1	0.59 (± 1.2072)			
T vs R2	0.90 (± 1.1897)			

Statistical analyses

No statistical analyses for this end point

Secondary: AUC(0-6h)

End point title AUC(0-6h)

End point description:

End point type Secondary

End point timeframe:

Treatment (overall period)

End point values	per protocol			
Subject group type	Subject analysis set			
Number of subjects analysed	54			
Units: ng*h/ml				
geometric mean (standard deviation)				
T vs R1	-0.05 (± 0.3250)			
T vs R2	0.21 (± 0.4083)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Collection of adverse events started after signing informed consent during the Pre-assignment period (non treatment emergent AEs) and during the treatment period of the trial (TEAEs).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.0
--------------------	------

Reporting groups

Reporting group title	Test
-----------------------	------

Reporting group description:

ibuprofen plus hyoscine butylbromide

Reporting group title	Reference 1
-----------------------	-------------

Reporting group description:

Brufen 400 mg

Reporting group title	Reference 2
-----------------------	-------------

Reporting group description:

Buscopan 10 mg

Serious adverse events	Test	Reference 1	Reference 2
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 54 (0.00%)	0 / 53 (0.00%)	0 / 53 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Test	Reference 1	Reference 2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 54 (1.85%)	0 / 53 (0.00%)	0 / 53 (0.00%)
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	1 / 54 (1.85%)	0 / 53 (0.00%)	0 / 53 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	1 / 54 (1.85%)	0 / 53 (0.00%)	0 / 53 (0.00%)
occurrences (all)	1	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported